Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beth Karlan

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Journal of the National Cancer Institute|April 18, 2026
Oncofertility patterns after the overturn of Roe v. WadeNikita V Baclig, Jordyn Silverstein, Vrushangi Shah, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 20, 2022
Frailty is independently associated with worse outcomes and increased resource utilization following endometrial cancer surgeryMorcos Nakhla, Cortney M Eakin, Ava Mandelbaum, et al.
Cancer Science|July 17, 2008
Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivoNaoki Wakimoto, Dong Yin, James O'Kelly, et al.
Plos One|June 3, 2021
Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancerChristine S Walsh, Mitchell Kamrava, Andre Rogatko, et al.
Genes, Chromosomes & Cancer|March 25, 2011
Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECKMarlena S Fejzo, Chuck Ginther, Judy Dering, et al.
Genes, Chromosomes & Cancer|July 11, 2008
Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification targetMarlena S Fejzo, Judy Dering, Chuck Ginther, et al.
Gynecologic Oncology|November 24, 2020
Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibitionMarlena S Fejzo, Hsiao-Wang Chen, Lee Anderson, et al.
Gynecologic Oncology|May 11, 2010
Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutationDanielle Vicus, Amy Finch, Barry Rosen, et al.
Gynecologic Oncology|June 24, 2010
Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tubeDanielle Vicus, Amy Finch, Ilana Cass, et al.
International Journal of Oncology|April 2, 2011
Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesisWenwen Chien, James O'Kelly, Daning Lu, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Journal of the National Cancer Institute|April 18, 2026
Oncofertility patterns after the overturn of Roe v. WadeNikita V Baclig, Jordyn Silverstein, Vrushangi Shah, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 20, 2022
Frailty is independently associated with worse outcomes and increased resource utilization following endometrial cancer surgeryMorcos Nakhla, Cortney M Eakin, Ava Mandelbaum, et al.
Cancer Science|July 17, 2008
Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivoNaoki Wakimoto, Dong Yin, James O'Kelly, et al.
Plos One|June 3, 2021
Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancerChristine S Walsh, Mitchell Kamrava, Andre Rogatko, et al.
Genes, Chromosomes & Cancer|March 25, 2011
Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECKMarlena S Fejzo, Chuck Ginther, Judy Dering, et al.
Genes, Chromosomes & Cancer|July 11, 2008
Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification targetMarlena S Fejzo, Judy Dering, Chuck Ginther, et al.
Gynecologic Oncology|November 24, 2020
Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibitionMarlena S Fejzo, Hsiao-Wang Chen, Lee Anderson, et al.
Gynecologic Oncology|May 11, 2010
Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutationDanielle Vicus, Amy Finch, Barry Rosen, et al.
Gynecologic Oncology|June 24, 2010
Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tubeDanielle Vicus, Amy Finch, Ilana Cass, et al.
International Journal of Oncology|April 2, 2011
Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesisWenwen Chien, James O'Kelly, Daning Lu, et al.
Pageof 9